Veradermics, Incorporated (MANE)
NYSE: MANE · Real-Time Price · USD
63.44
+1.52 (2.45%)
Mar 24, 2026, 11:55 AM EDT - Market open
Veradermics Market Cap
Veradermics has a market cap or net worth of $2.37 billion as of March 24, 2026.
Market Cap
2.37B
Enterprise Value
2.41B
1-Year Change
n/a
Ranking
Category
Stock Price
$63.44
Market Cap Chart
Since the IPO on February 4, 2026, Veradermics's market cap has increased from $1.32B to $2.37B, an increase of 78.89%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 20, 2026 | 2.20B | 3.48% |
| Mar 19, 2026 | 2.12B | -3.56% |
| Mar 18, 2026 | 2.20B | -3.37% |
| Mar 17, 2026 | 2.28B | 7.23% |
| Mar 16, 2026 | 2.13B | 7.86% |
| Mar 13, 2026 | 1.97B | 2.39% |
| Mar 12, 2026 | 1.93B | 1.06% |
| Mar 11, 2026 | 1.91B | 0.75% |
| Mar 10, 2026 | 1.89B | -1.31% |
| Mar 9, 2026 | 1.92B | 5.68% |
| Mar 6, 2026 | 1.81B | -0.12% |
| Mar 5, 2026 | 1.82B | 2.68% |
| Mar 4, 2026 | 1.77B | 5.04% |
| Mar 3, 2026 | 1.68B | -3.30% |
| Mar 2, 2026 | 1.74B | 1.68% |
| Feb 27, 2026 | 1.71B | 6.85% |
| Feb 26, 2026 | 1.60B | 1.75% |
| Feb 25, 2026 | 1.57B | -3.70% |
| Feb 24, 2026 | 1.64B | -2.69% |
| Feb 23, 2026 | 1.68B | 1.15% |
| Feb 20, 2026 | 1.66B | -7.93% |
| Feb 19, 2026 | 1.80B | -3.51% |
| Feb 18, 2026 | 1.87B | 5.70% |
| Feb 17, 2026 | 1.77B | 9.02% |
| Feb 13, 2026 | 1.62B | -2.21% |
| Feb 12, 2026 | 1.66B | 0.91% |
| Feb 11, 2026 | 1.64B | 8.88% |
| Feb 10, 2026 | 1.51B | 9.24% |
| Feb 9, 2026 | 1.38B | -3.77% |
| Feb 6, 2026 | 1.44B | 3.55% |
| Feb 5, 2026 | 1.39B | 4.78% |
| Feb 4, 2026 | 1.32B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Maze Therapeutics | 2.31B |
| Immunome | 2.26B |
| Disc Medicine | 2.22B |
| Day One Biopharmaceuticals | 2.21B |
| Wave Life Sciences | 2.21B |
| Apellis Pharmaceuticals | 2.20B |
| Syndax Pharmaceuticals | 2.14B |
| Galapagos NV | 2.11B |